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Abstract 
 
Poly(lactide-co-glycolide), or PLGA, microspheres offer a widely-studied biodegradable option 
for controlled release of therapeutics. An array of fabrication methodologies have been 
developed to produce these microspheres with the capacity to encapsulate therapeutics of various 
types; and produce microspheres of a wide range of sizes for different methods of delivery. The 
encapsulation, stability, and release profiles of therapeutic release based on physical and 
thermodynamic properties has also been studied and modeled to an extent. Much research has 
been devoted to tailoring formulations for improved therapeutic encapsulation and stability as 
well as selective release profiles.  
 
Despite the breadth of available research on PLGA microspheres, further analysis of 
fundamental principles regarding the microsphere degradation, formation, and therapeutic 
encapsulation is necessary. This work aims to examine additional fundamental principles related 
to PLGA microsphere formation and degradation from solvent-evaporation of preformed 
polymer. In particular, mapping the development of the acidic microenvironment inside the 
microsphere during degradation and erosion is discussed. Also, the effect of macromolecule size 
and conformation is examined with respect to microsphere diameter and PLGA molecular 
weight. Lastly, the effects of mechanical shearing and protein exposure to aqueous media during 
microsphere formation are examined.  
 
In an effort to better understand the acidic microenvironment development across the 
microsphere diameter, pH sensitive dye conjugated to protein that undergoes conformational 
change at different acidic pH values was encapsulated in PLGA microspheres of diameters 
ranging from 40 µm to 80 µm, and used in conjunction with fluorescence resonance energy 
transfer to measure the radial pH change in the microspheres. Qualitative analysis of confocal 
micrographs was used to correlate fluorescence intensity with pH value, and obtain the radial pH 
across the center of the microsphere.  
 
Therapeutic encapsulation and release from polymeric microspheres is governed by an 
interconnected variety of factors, including the therapeutic itself. The globular protein bovine 
serum albumin, and the elongated and significantly smaller enzyme, lysozyme, were 
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encapsulated in PLGA microspheres ranging from 40 µm to 80 µm in diameter. The initial 
surface morphology upon microsphere formation, release profiles, and microsphere erosion 
characteristics were explored in an effort to better understand the effect of protein size, 
conformation, and known PLGA interaction on the formation and degradation of PLGA 
microspheres and macromolecule release, with respect to PLGA molecular weight and 
microsphere diameter.  
 
In addition to PLGA behavior and macromolecule behavior, the effect of mechanical stresses 
during fabrication was examined. Two similar solvent extraction techniques were compared for 
the fabrication of albumin loaded microspheres. In particular, the homogeneity of the 
microspheres as well as capacity to retain encapsulated albumin were compared. This 
preliminary study paves the way for a more rigorous treatment of the effect of mechanical forces 
present in popular microsphere fabrication.  
 
Several factors affecting protein release from PLGA microspheres are examined herein. The 
technique explored for spatial resolution of the pH inside the microsphere proved mildly 
effective in producing a reliable method of mapping microsphere pH changes. However, notable 
trends with respect to microsphere size, PLGA molecular weight, and microsphere porosity were 
observed. Proposed methods of improving spatial resolution of the acidic microenvironment are 
also provided. With respect to microsphere formation, studies showed that albumin and 
lysozyme had little effect on the internal homogeneity of the microsphere. Rather, ionic 
interactions with PLGA played a more significant role in the encapsulation and release of each 
macromolecule. Studies also showed that higher instances of mechanical stress led to less 
homogeneous microspheres with lower protein encapsulation. This suggests that perhaps instead 
of or in addition to modifying the microsphere formation formulation, the fabrication technique 
itself should be more closely considered in achieving homogeneous microspheres with desired 
loading.  
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Chapter 1. Introduction 
 
1.1 Motivation for Controlled Release 
Controlled therapeutic release has been a topic of interest for decades. Controlled release of 
therapeutics is often preferred over traditional therapeutic administration, in which the drug is 
delivered as a bolus, potentially resulting in drug concentrations exceeding the maximum 
tolerated dose upon initial administration, and having a limited time frame for efficacy as the 
concentration in the body is depleted. A delivery method that provides nearly constant drug 
concentration within the therapeutic window would allow more effective treatment of diseases 
and would minimize the toxicity risks to the body. Additionally, controlled release may reduce 
the dosage frequency, and offer site-specific delivery of the therapeutic.  
 
1.2 Methods of Controlled Release 
A wide variety of controlled release devices are currently available. These include implantable 
devices, which are implanted into muscle tissue or under the skin. Such implantable devices 
include Biophan™’s nanomagnetic drug eluting devices; InterStim® Therapy for urinary control 
from Medtronic™; and active and inactive drug delivery systems offered by MicroCHIPS™.  
These systems provide high localized therapeutic concentrations, preferred for targeted delivery. 
However, they are sometimes doubly invasive since non-biodegradable components must be 
removed once the therapeutic is depleted. Other delivery methods include implantable pumps, 
which provide excellent control of drug concentration and release rate and allow for extended 
release (up to 1 year), but must be removed upon drug depletion.  
 
Preferred controlled release options involve the use of minimally invasive biodegradable 
materials to administer therapeutics. Several types of biodegradable systems are currently 
employed, including gels and hydrogels, liposomes, polymeric microspheres and other 
geometries. In addition to biodegradability, these options are advantageous in that they can be 
locally injected. Gels are further advantageous because of their potential for tailored response to 
the local environment, including temperature and pH.  One of the main disadvantages of gels is 
their poor mechanical strength. Liposomes have been explored for controlled release, but provide 
poor control of drug release rates and are relatively unstable.  
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1.3 Polymeric Microspheres for Drug Delivery 
Biodegradable polymeric microspheres are of major interest due to their ease of fabrication and 
administration. Microspheres can be administered by several routes. The route of administration 
selected depends heavily upon the stability of the therapeutic and the type of delivery desired. 
Oral administration is limited to systemic delivery of highly stable therapeutics. Injection allows 
both systemic and localized delivery of sturdy and some delicate therapeutics. Small micron and 
nanosphere preparations allow administration by inhalation. 
 
A variety of polymers have been studied for drug delivery applications, including 
polyorthoesters and polyanhydrides [1], which degrade by surface erosion; naturally occurring 
polymers such as chitosan and cellulose [2-4]; and bulk eroding polyesters such as poly(lactide-
co-glycolide). Several factors can be adjusted to help tailor the encapsulation efficiency, stability 
and release of therapeutic [5-12]. The mechanism of polymer degradation is one of the 
controlling factors in therapeutic release behavior. Constant therapeutic release rates can be 
achieved by using surface eroding polymers, such as polyanhydrides [13].  Such hydrophobic 
polymers minimize the absorption of water in the polymer matrix, allowing surface erosion to 
dominate. The rate of release is then proportional to the surface area of the microsphere. Bulk-
eroding polymers, such as poly(lactide-co-glycolide), allow water to penetrate the polymer 
matrix, causing degradation to occur both topically and throughout the polymer matrix. This 
leads to an early period of release exemplified by surface erosion, but a later burst caused by 
erosion in the bulk, typically giving a sigmoidal release trend.  
 
Additional characteristics of the polymer and drug affect therapeutic release and polymer 
degradation. For example, research has shown that by increasing the lactide:glycolide ratio,  the 
polymer degradation rate, and thus the therapeutic release rate can be slowed significantly [9]. 
Polymer molecular weight can also be adjusted to tailor release profiles. Typically, increasing 
polymer molecular weight gives slower release and polymer degradation [6-9]. Studies have also 
shown that smaller microspheres exhibit faster release in both surface and bulk eroding 
microspheres. However, in the case of bulk erosion, the mechanism of release can be more 
complex. In the case of PLGA microspheres, the rate of release in larger microspheres exhibits a 
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marked increased after some period of incubation by the presence of an “erosive burst” from the 
bulk [14].  This erosive burst is caused by the buildup of acidic byproducts inside the 
microsphere, which accelerates the rate of polymer degradation, leading to a more significant 
increase in release rate when the pore sizes and pore network throughout the microsphere have 
developed such that greater diffusion can occur. Research has also shown that drug distribution 
in larger microspheres can be increased toward the surface of the microsphere, due to slower 
solvent evaporation during microsphere hardening caused by longer diffusion distances [6]. This 
aggregation of drug toward the surface can in some cases negate the previously described release 
behavior in larger microspheres.  
 
Therapeutic release behavior can also be affected by the thermodynamics of the encapsulated 
material. Since release is dominated by diffusion, in theory, smaller molecules release faster than 
larger molecules. However, studies have suggested that the positively charged enzyme lysozyme 
interacts with PLGA inside the matrix, slowing its release rate [15]. Depending on the polymer 
used, the composition of the polymer can mitigate these interactions, as is the case with poly[1,6-
bis(p-carboxyphenoxy)hexane] and poly(sebacic anhydride) copolymer (CPH:SA). Research has 
shown that with CPH:SA copolymer, the interactions of the encapsulated compounds with a 
selected monomer in the copolymer composition led to release mimicking the degradation 
behavior of the monomer toward which each compound preferentially migrated [16]. 
 
1.4 PLGA Microspheres 
The biocompatible polymers poly(lactide-co-glycolide), or PLGA, and poly(lactic acid), or PLA, 
have been studied for decades for drug delivery applications. As previously mentioned, varying 
the ratio of lactide to glycolide in PLGA can significantly influence the rate of degradation, with 
longer release profiles observed for compositions containing more lactide [17-18]. Studies have 
also shown that increasing the molecular weight of PLGA, as with other bulk-eroding polymers, 
slows the release rate of model protein [19-20]. Unique release profiles have been achieved from 
PLGA microspheres by varying the microsphere diameter [6,21]. Additionally, comparative 
studies have shown a slight effect on the release rate with varying protein size at low loading 
concentrations [22].  Lysozyme has been shown to release more slowly than albumin from 
PLGA microspheres due to interaction of the lysozyme with PLGA [18]. 
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1.4.1 PLGA Microsphere Modification and Protein Stability 
The fabrication process, which typically involves the use of an organic solvent, can be damaging 
to therapeutics. In addition, hydrophilic PLGA microspheres will allow water diffusion into the 
polymer matrix, causing bulk-erosion and the development of an acidic microenvironment [23-
25]. This microenvironment can destabilize an encapsulated therapeutic. A variety of methods 
have been employed to better control the porosity and encapsulation of proteins, as well as to 
stabilize therapeutic while inside PLGA microspheres [26-27]. Emulsion stabilizers such as 
Pluronic and poly(vinyl alcohol) are often employed to control solvent evaporation rate. Studies 
have shown that by increasing the concentration of poly(vinyl alcohol) in the secondary 
emulsion, the solvent evaporation rate can be reduced, leading to more homogeneous 
microspheres [28]. Researchers have successfully stabilized drugs inside PLGA microspheres by 
adding pH buffering agents, and other excipients [29-30].  
 
1.4.2. pH Dependence of PLGA Degradation and Protein Release 
Ester-based polymeric microspheres degrade by autocatalytic degradation. During degradation, 
acidic byproducts are generated and the polymer hydrolysis is acid catalyzed. The rate of 
diffusion of these byproducts out of the microsphere is limited in proportion to the radius and 
porosity of the microsphere. Entrapment of these acidic moieties causes a drop in the internal pH 
of the microspheres and leads to more rapid degradation in the core compared to near the 
surface. This pH drop expectedly becomes more pronounced as the size of microspheres 
increases, and as the polymer molecular weight increases due to diffusion limitations. This 
decreased pH threatens to denature and/or inactivate encapsulated therapeutics. The presence of 
a low pH microenvironment inside degrading microspheres incubated at neutral pH has been 
observed, and determined to be as low as pH 1.5 [26-28]. Little work has been done to provide a 
more rigorous treatment that maps the pH across the microsphere to its lowest value, and 
examines the internal pH based on microsphere size.  
 
1.5 Microsphere Fabrication Methods 
Polymeric microspheres are formed either during the polymerization process or using preformed 
polymer. Commonly used methods for polymerization-based polymeric microsphere fabrication 
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include interfacial polymerization, emulsion/solvent extraction, and polymer extrusion. The 
applicability of each technique is limited by the polymer and therapeutic.  Interfacial 
polymerization [30-32] commonly employs suspension [33-34], emulsion [36-38], or dispersion 
polymerization [39] to achieve particle fabrication during the polymerization process.  
 
Particles formed by suspension polymerization are limited to the solvent droplet sizes in solution 
once the polymer-drug mixture is added to an immiscible bath. This method also requires 
mechanical agitation for the formation of microspheres. Emulsion polymerization requires the 
formation of micelles in an aqueous solution, and poses problems with encapsulation of the drug 
if it is not trapped with the polymer inside the micelle. It is subsequently limited to water-
insoluble proteins and therapeutics. Particles formed using dispersion polymerization are made in 
a single-phase solution. This technique affords the use of a variety of monomers, but requires 
that the therapeutic and monomers are both miscible in the chosen solvent.  
 
Microsphere formation using preformed polymer typically requires some form of solvent 
removal. Solvent extraction involves dissolving preformed polymers and the therapeutic either 
separately or in the same solvent, then breaking the solution into droplets using external physical 
force, such as through homogenization or sonication [40-42]. The solvent is then removed by 
dissolution into aqueous media, or by gas based drying. The presence of residual solvents in the 
final particles must be monitored, as they pose toxicity threats.  Also, the amount of 
microspheres that can be made is limited by the batch size.  
 
Microspheres from preformed polymer can also be produced by extrusion of the polymer-drug 
solution from a narrow orifice [43-44]. Unlike the aforementioned techniques, this process is 
continuous, and allows more precise control of particle size. Control of particle size is necessary 
for improved control of therapeutic release profiles, i.e. concentration of drug released and the 
length of time for release. Thus, techniques that provide a narrower size distribution are favored.  
 
A variety of techniques that produce microspheres of narrow size-distribution have been 
developed [45-49]. Narrow size distributions can be achieved using an extrusion-style technique 
developed at the University of Illinois, Urbana-Champaign, in which acoustic excitation is used 
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to break a polymer stream into particles of a single size [5, 50-54]. This method employs a dual-
nozzle setup for microsphere formation in which emulsified or co dissolved drug and polymer 
are fed through an inner nozzle, and surrounded by a carrier phase. A schematic of the precision 
fabricator is shown in Figure 1.1. By varying parameters such as the flow rates of the organic 
phase and the carrier phase, and the frequency and amplitude of vibration, microsphere size can 
be controlled. In addition, a variety of microsphere and microcapsule compositions can be used 
with this technique. [5,6,21,55-58] 
 
 
Figure 1.1. Schematic of Precision Fabrication Device. [5] 
 
 
1.6 Research Aims 
A wide variety of studies on PLGA microspheres have been done to date. Researchers have not 
only attempted to understand the fundamental governing principles of PLGA microsphere 
degradation and protein release and stability, but have also developed formulations and methods 
of fabrication that overcome many obstacles associated with employing PLGA microspheres in 
pharmaceutical applications. Nevertheless, additional understanding of the governing principles 
that influence PLGA microsphere behavior is needed. Using precision fabrication technology 
previously described, this study focuses on three aims. Particularly with respect to microsphere 
size and PLGA molecular weight, this study aims to better understand the development of the 
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acidic microenvironment inside degrading PLGA microspheres; to understand differences in 
release of macromolecules of different size and conformation; and to gain insight into the effect 
of shearing by the fabrication process on the formation of PLGA microspheres. Chapter 2 
focuses on the development of a technique to map intraparticle pH. Chapter 3 focuses on the 
release behavior of albumin and lysozyme from PLGA microspheres of varying diameter 
produced from PLGA of varying molecular weight. Chapter 4 examines the effect of precision 
fabrication and homogenization on the production of PLGA microspheres.  
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Chapter 2. Measurement of Intraparticle pH in Degrading PLGA Microspheres 
 
2.1 Motivation 
Though PLGA is a heavily studied material for drug delivery, some characteristics of its 
behavior warrant further investigation. In particular, the rate of diffusion of acidic degradation 
byproducts out of the microsphere is limited in proportion to the square of the radius and 
porosity of the microsphere. Accumulation of these acidic moieties causes a drop in the internal 
pH of the microspheres and leads to more rapid degradation in the core compared to near the 
surface. This pH drop expectedly becomes more pronounced as the size of microspheres 
increases, and as the polymer molecular weight increases due to diffusion limitations. This 
decreased pH threatens to denature and/or inactivate encapsulated therapeutics.  
 
The presence of a low pH microenvironment inside degrading microspheres has been 
established, and determined to be as low as pH 1.5 [1-3]. Little work has been done to provide a 
more rigorous treatment that maps the pH across the microsphere and examines the internal pH 
based on microsphere size. Herein, the radial development of the acidic microenvironment inside 
PLGA microspheres is determined with respect to PLGA molecular weight and microsphere 
diameter. 
 
2.2 Previous Work 
In an earlier study, an initial attempt at using pH sensitive fluorescent dye to map the internal pH 
across microspheres was made [5]. The pH sensitive dye fluorescein-5-isothiocyanate (FITC) 
and pH insensitive dye AlexaFluor 633 (AF 633) were used to map the pH inside degrading 
PLGA microspheres from pH 6.5 to pH 4. Figure 2.1 shows the variation in radial pH of 12 
microspheres of 32 µm diameter at day 3. Data showed a swift drop in pH toward the center of 
the microspheres, with pH reaching the lowest measurable value as early as 3 days. The most 
significant effect was the tapering of the pH across the microsphere. The pH drops quickly with 
decreasing radial position near the surface. 
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Figure 2.1. pH of twelve individual microspheres used to find the average pH of the 32 µm 
microspheres at day 3. 
 
The extent of the pH drop at the center of the microsphere and across the radial distance, along 
with the rate of this change in pH are of great interest. Thus this study aimed to determine the 
extent of the pH drop by employing the principles of fluorescence resonance energy transfer 
(FRET) in conjunction with the pH-induced conformational change of BSA at low pH. Efforts to 
accomplish this goal are discussed herein.  
 
2.3 Methods 
 
2.3.1 Materials 
Poly(D,L-lactide-co-glycolide) (PLGA) polymers of 50:50 lactide:glycolide ratio and inherent 
viscosities (i.v.) of 0.20, 0.41, and 0.61 dL/g, were obtained from Durect Corporation. These 
PLGA polymers are hereafter referred to by their relative molecular weights of 11 kDa, 25 kDa, 
and 48 kDa, respectively. Lyophilized bovine serum albumin was obtained from Sigma-Aldrich. 
Carboxyfluorescein or FAM, obtained from Molecular Probes, was selected as a pH sensitive 
dye in the range of pH 4-7. 5-(and-6)-Carboxytetramethylrhodamine succinimidyl ester 
(TAMRA), obtained from Molecular Probes, was selected as a pH insensitive dye in the range of 
pH 4-7. Additionally, its excitation wavelength falls inside the range of FAM’s emission spectra, 
which is a necessary component for FRET. Dimethyl sulfoxide (DMSO) was purchased from 
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Fisher Scientific. PD-10 desalting columns were purchased from Amersham Biosciences.  
Tween 80 was obtained from Fisher Scientific, and used as a surfactant during release studies. 
Phosphate buffered saline tablets were obtained from MP Biomedicals, and dissolved in milli-Q 
water. Poly(vinyl alcohol) (PVA), 88% hydrolyzed, was obtained from Polysciences, dissolved 
in Milli-Q water, and diluted to the specified concentrations. Reagent grade dichloromethane 
(DCM) and HPLC grade chloroform were obtained from Fisher Scientific.  
 
2.3.2 Protein Labeling 
Dual labeled bovine serum albumin was made by covalently conjugating FAM and TAMRA to 
albumin. Briefly, for each formulation, 40 milligrams of albumin were dissolved in 4 mL of 
sodium bicarbonate at pH 8.3±0.05. Several formulations containing varied amounts of FAM 
and TAMRA dissolved in 40 µL of DMSO each were pipetted into the foil-wrapped vial 
containing dissolved albumin. The solution was stirred on a stir plate for 60 minutes at room 
temperature. The labeled albumin and unattached dye were then separated using a PD-10 
desalting column pre-equilibrated with sodium bicarbonate buffer. The collected protein was 
then frozen and lyophilized. 
 
The degree of labeling for each conjugate was determined by dissolving 1.0 mg of labeled 
protein in 1.0 mL of milli-Q H2O. The absorbance was taken at the wavelengths shown in Table 
2.1.  Readings were zeroed against 1.0 mL of milli-Q H2O. The values were then used to 
calculate the degree of labeling according to the method established by Molecular Probes 
(www.probes.com). Labeling results are discussed in further details in the section 2.4.1. For 
microspheres discussed herein, the labeling ratio FAM : TAMRA was 7.1 : 1.  
 
Table 2.1. Excitation wavelengths of selected dyes and Albumin 
Dye or Protein Excitation          
Wavelength (nm) 
Extinction 
Coefficient 
FAM 494 68000 
TAMRA 555 65000 
Albumin 280 -- 
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2.3.3 Microsphere Fabrication and Sizing 
 
Uniform microspheres of roughly 40 µm, 60 µm, and 80 µm diameter were fabricated using the 
precision fabrication technique described in chapter 1. In short, PLGA was dissolved in DCM at 
10 % (w/v). Albumin was dissolved in milli-Q water. The amount of water used was maintained 
at a 1:10 (H2O : DCM) ratio. Albumin concentration was selected to provide 10 % (w/w) loading 
of the PLGA, with dual-labeled albumin comprising 2.5% of the total albumin concentration. 
The PLGA and macromolecule solutions were emulsified by sonication on ice at 60% amplitude 
for 1 minute, and fed into the precision fabricator. Carrier phase and emulsion phase flow rates, 
and frequency and amplitude of vibration were selected to produce the desired microsphere size.  
 
Microspheres were collected in 1% PVA solution, and allowed to harden under stirring for three 
hours. Microspheres were subsequently washed with three aliquots of milli-Q water, then frozen 
and lyophilized for 48 hours prior to use. Lyophilized microspheres were stored at -20ºC under 
desiccant. Microspheres were sized using a Beckman-Coulter Multi-Sizer III, with a minimum 
count of 10,000 microspheres. Microsphere diameters are reported as the mean diameter, and 
include the standard deviation and R90, which is the ratio of the largest to smallest microsphere 
within the 10% outer limits of measurement. 
 
2.3.4 Albumin Loading  
 
For each set of microspheres, approximately 5 mg of microspheres were dissolved in 100 µL of 
DMSO. Twenty microliters of the dissolved PLGA and macromolecule solution were pipetted 
into 1 mL of PBS while vortexing. Samples were incubated at 37ºC for 1 hour with agitation, and 
then centrifuged at 10000 rpm for 10 minutes to pellet the polymer. The supernatant was 
removed and replaced with 1 mL of fresh PBS while vortexing. The samples were then incubated 
for an additional 30 minutes at 37ºC. The concentration of protein in the supernatant was 
determined for both supernatants using BCA assay, then summed for each set of microspheres. 
The encapsulation efficiency or loading is reported as the measured concentration of albumin as 
a percent of theoretical loading during encapsulation.  
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2.3.5 In-Vitro Release and PLGA Degradation Studies 
 
To obtain protein release behavior, 10 mg of microspheres were suspended in 1.25 mL of PBS 
with 0.05% Tween 80 (pH 7.2 ± 0.05), and incubated at 37ºC with agitation. One mL of 
supernatant was extracted at various time points, and replaced with fresh buffer. Protein 
concentration in supernatants was determined using BCA assay.  
 
Microsphere surface morphology and porosity changes were observed by scanning electron 
microscopy. Microspheres were washed with milli-Q water three times, then freeze-fractured and 
mounted on carbon tape, and allowed to dry. Prepped samples were sputter coated for 30 seconds 
at 20 mA with gold-palladium using an Emitech K-575 Sputter Coater. Scanning electron 
micrographs were then acquired using a JEOL 6060 LV scanning electron microscope at 5 kV 
accelerating voltage.  
 
2.3.6 Radial pH Mapping 
The radial pH of the microspheres was determined by quantitative analysis of confocal 
fluorescence micrographs obtained from dual-labeled protein loaded microspheres.  Stock 
solutions of 500 mM pH buffers ranging from pH 1.5 to 7 were prepared using acid-salt 
combinations given in Table 2.2. Buffers were titrated to the desired pH using 0.1 M HCl and 0.1 
M NaOH. To determine a calibration curve, microspheres were soaked for 12 hours at 37ºC in 
buffers of pH 1.5 to 7 ± 0.05. Microspheres were then imaged using a Leica SP2 Laser Scanning 
Confocal Microscope with Leica Confocal Software. The microscope was focused at the center 
of the microspheres by adjusting the focus to achieve an image of the largest diameter. Optimal 
PMT and Offset settings were determined by saturating images of microspheres at each pH, then 
decreasing the PMT and gain until saturation was eliminated. Images were analyzed using 
IMAGE J (http://rsb.info.nih.gov/ij/) software. The images were first converted to 8-bit format 
and smoothed once. The FAM or FRET image was then divided by the TAMRA image, and a 
32-bit result obtained, using the Image Calculator feature. The radial intensities of a minimum of 
ten microspheres per batch were determined using the Radial Profile Plugin feature, and then 
averaged to determine a single average intensity inside the microsphere. Fluorescence intensity 
ratio versus pH calibration curves were created for each set of microspheres. 
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Microspheres from each set of size and polymer molecular weight were subjected to a 40-
day degradation study. For each set approximately 10.0 mg of microspheres were suspended in 
1.25 mL of PBS (pH 7.2±0.5) with 0.05% Tween 80. Microspheres were incubated on a roto-
rack at 37ºC. At various time points during the study, a sample of microspheres was removed. 
Also, 1.0 mL of supernatant was removed from each sample and replaced with 1.0 mL of fresh 
PBS (pH 7.2±0.5) with 0.05% Tween 80 every seven days to maintain buffer pH. Microspheres 
were imaged using confocal microscopy at the optimal PMT and gain settings determined during 
calibration. The average radial intensity for a minimum of ten microspheres was determined 
using IMAGE J. The values obtained were compared with pH versus intensity ratio calibration 
plots to determine the pH across the microspheres.  
 
Table 2.2. pH Buffer Compositions for pH versus Fluorescence Intensity Calibration 
Curves. 
Acid / Salt Pair pH 
Acid Concentration 
(g/L) 
Salt Concentration 
(g/L) 
1.5 16.8 2.5 
2 10.5 6.4 
2.5 4.8 12.7 
3 1.8 18.4 
HOCOCH:CHCOOH  / 
HO2CCH=CHCO2H 
3.5 0.6 21.4 
4 14.0 1.8 
4.5 10.6 4.2 
5 6.0 7.6 
CH3COOH / 
CH3COONa 3H2O 
5.5 2.5 10.2 
6 23.9 4.2 
6.5 18.9 10.6 KH2PO4 / K2HPO4 
7 11.4 20.2 
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2.4 Results and Discussion 
 
2.4.1 Dual-Labeled Albumin Selection 
To optimize the incremental fluorescence intensity with respect to pH, FAM and TAMRA 
concentrations were selected to vary the labeling ratio from (FAM : TAMRA) 1:1, 1:2, 2:1, and 
so on. After the degree of labeling was determined, dissolved protein was pipetted into pH buffer 
standards and the fluorescence intensity at each pH determined for FAM (488 nm / 518 nm), 
TAMRA (555 nm / 580 nm), and FRET (488 nm / 580 nm). Although it is recommended to use 
494 nm for FAM, the confocal microscope has only 488 nm laser available, thus solution testing 
was performed at 488 nm. Figure 2.2 shows fluorescence intensity versus pH for 2:1 dual-labeled 
albumin and 7:1 dual-labeled albumin using FRET. The increments are larger for 7:1 than 2:1. 
However, over the pH range of interest with FRET (pH 1 to 4), the total change in intensity is 
only 0.2. Previous studies have demonstrated that a smaller incremental change in intensity is 
observed with confocal than with fluorescence in solution. A change of 0.2 over such a large pH 
range would equate to between 0.1 to 0.15 incremental change over the same pH range with 
confocal. Given the propensity for larger variations in intensity across the microsphere when 
using confocal microscopy than in solution, the values would overlap, and not provide useful 
determination between pH values. Ultimately, it was determined that a ratio of 7:1 was the most 
promising, with an incremental change of 0.4 in fluorescence intensity in solution from pH 1.5 to 
4, as shown in Figure 2.2. 
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Figure 2.2. Fluorescence intensity versus pH of dual-labeled albumin in pH buffer solution. 
 
2.4.2 pH Standard Curves 
Analysis of microspheres containing 2.5% dual-labeled albumin showed that the concentration of 
dual-labeled albumin was too high. Standard curves could not be obtained due to inconsistencies 
in the measured intensities between pH values, which were likely caused by self-quenching of 
the dye fluorescence. Thereafter, the dual-labeled albumin was again tested in pH buffer solution 
to determine the concentration that exhibited no quenching. It was determined that dual-labeled 
albumin incorporated at 1% of the total albumin concentration would be of utility. Microspheres 
were fabricated at 40 µm, 60 µm, and 80 µm for each PLGA molecular weight.  
 
Standard curves were established using 500 mM pH buffers. Confocal micrographs of 
microspheres soaked in pH buffer for 12 hours are shown in Figure 2.3. Standard curves for each 
set of microspheres are shown by PLGA molecular weight in Figures 2.4 – 2.6. Notice that there 
are two curves present for each set. To map pH from neutral to acidic, the natural pH sensitivity 
of fluorescein was used over the pH 4 to 7 range, and FRET was used from pH 1.5 to 4. The 
excitation and emission wavelengths for each are given in section 2.4.1. The two curves do 
overlap in intensity readings, but the values are exclusive to the technique employed. In theory, 
when the pH reaches 4, further analysis would be performed using FRET. The standard curves 
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for 11 kDa PLGA are skewed, making them difficult to use over the full pH range. However, the 
curves are much cleaner for the 25 kDa and 48 kDa PLGA. Note also that the 80 µm 
microspheres allow the best incremental change in FRET intensity versus pH in the 25 kDa and 
48 kDa microspheres. Because these images are taken at the center of the microsphere, the 
higher PLGA molecular weight and larger focus distance help minimize quenching of the energy 
transfer, allowing greater resolution of the FRET behavior.  
 
In all curves, there is a distinctive drop in the FRET intensity at pH 4. This is expected due to the 
conformational change of albumin near pH 4. At lower pH, albumin exists in a partially unfolded 
form. The properly folded conformation above pH 4 puts the dyes in even closer proximity, 
likely leading to quenching at pH 4. Thus, pH 4 is omitted from the FRET analysis. Also, there is 
clear quenching in the 11 kDa microspheres, which increasingly skews the FRET curves with 
decreasing microsphere size. Thus, analysis would only be useful for pH 1.5 to 3. However, the 
extent of the gap between pH 4 and pH 3 make it difficult to determine the point at which FRET 
analysis should be employed. Therefore, 11 kDa PLGA microspheres can only be analyzed using 
the natural fluorescence of FAM, which is useful from pH 4 only to pH 6 for all microsphere 
diameters. 
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Figure 2.3. Confocal micrographs of microspheres soaked in pH buffer for 12 hours. 
 21
pH
1 2 3 4 5 6 7
FR
ET
 (p
H
 1
-4
) a
nd
 F
AM
 (p
H
 4
-7
) 
Av
er
ag
e 
R
ad
ia
l I
nt
en
si
ty
0.0
0.5
1.0
1.5
2.0
2.5
3.0
43 µm FRET
43 µm FAM
65 µm FRET
65 µm FAM
87 µm FRET
87 µm FAM
FAMFRET
FR
ET
 (p
H
 1
-4
) a
nd
 F
AM
 (p
H
 4
-7
) 
Av
er
ag
e 
R
ad
ia
l I
nt
en
si
ty
 
Figure 2.4. FRET (left) and FAM (right) Based Standard Curves for 11 kDa PLGA 
Microspheres. 
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Figure 2.5. FRET (left) and FAM (right) Based Standard Curves for 25 kDa PLGA 
Microspheres. 
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Figure 2.6. FRET (left) and FAM (right) Based Standard Curves for 48 kDa PLGA 
Microspheres. 
 
2.4.3 pH Mapping 
Figure 2.8 shows confocal micrographs of microspheres over 21 days. Some change in intensity 
throughout the microsphere is visible, but cannot be clearly distinguished in these images. It is 
interesting to see the swell of the microspheres over time. The 45 µm microspheres from 48 kDa 
PLGA shown in Figure 2.7 exhibit a 14% increase in diameter. This swelling effect is even more 
pronounced in larger microspheres at lower molecular weight, with up to 62% swelling visible 
by day 21 in 87 µm, 11 kDa PLGA microspheres (not shown). Loss of spherical form occurs by 
day 21 in larger microspheres as well. 
 
The normalized radial pH of 48 kDa PLGA microspheres incubated at various time points are 
shown in Figures 2.8 to 2.10. All values shown were obtained using the natural fluorescence of 
FAM. Values were not adjusted within the limitations of the standard curve to maintain the 
integrity of the curvature of the radial profiles. It should be noted that for reasons described in 
the next section, the data presented are not necessarily valid pH measurements. However, the 
data are discussed in relation to the shift of the radial distribution as opposed to actual pH values.  
 
 23
These data show a significant decrease in pH across the microsphere within the first 3 days of 
incubation. For all three sizes, the pH does not appear to fall below pH 4 during the first 21 days 
of incubation, making incorporation of the FRET analysis unnecessary.  
 
The normalized radial pH of 25 kDa PLGA microspheres incubated at various time points are 
shown in Figures 2.11 to 2.13. As with 48 kDa PLGA microspheres, all values shown were 
obtained using the natural fluorescence of FAM. Values were not adjusted above the values 
within the limits of the standard curve to maintain the integrity of the curve. The pH behavior is 
similar to that observed in the 48 kDa PLGA microspheres, showing a significant decrease in the 
pH in the first 3 days of incubation. Again, the pH does not appear to fall below pH 4 during the 
first 21 days of incubation, making incorporation of the FRET analysis negligible.  
 
Previous efforts to map the radial pH change showed the pH falling to and below pH 4 within the 
first 7 days for most microspheres, along with a radial decrease in the pH with decreasing radial 
position. [5] This low pH is expected due to the autocatalytic degradation taking place inside the 
microspheres. However, the pH in this data tends to reach a point of consistency between pH 4 
and 5, dropping to pH 4, then rising to pH 5 and holding in neutral pH ranges thereafter. It is 
possible that the pH genuinely does not reach the levels of acidity previously observed, given the 
level of surface porosity in these microspheres, as shown in Figure 2.14. Ding et al. showed in a 
similar study that the pH was maintained around 5 during the first month of incubation in porous 
microspheres [4]. Transport limitations are minimized by the increased porosity, and acidic 
byproducts are able to diffuse quickly out of the microsphere, allowing opportunity for a less 
acidic microenvironment. Thus, a similar effect may be experienced in the microspheres used for 
this study.  
 
Though the pH is not clearly defined at the highest pH, the shape of the pH curves are of 
importance. For both PLGA molecular weights, variations in the shape of the pH curve from the 
center to the edge of the microsphere become less distinguishable with increasing microsphere 
diameter. The pH becomes more consistent across the diameter of the microsphere in 
microspheres above 40 µm in size. This phenomenon is inconsistent with the previous study 
involving less porous microspheres, which showed the radial pH drop is faster with larger 
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microspheres, with the radial pH clearly falling below pH 4 as early as day 3 in the 87 µm 
microspheres [5].  
 
It is also interesting to see the pH change that occurs at day 21. For all microspheres, the pH 
increases from the lowest pH at day 14. In 40 µm microspheres, the increase in pH is significant 
compared with the increase in 60 µm and 80 µm microspheres. GPC studies have shown a 
roughly 20% decrease in PLGA molecular weight at day 14, 21, or both [6-7]. This increase in 
pH at day 21 is further confirmation of a burst release from the microspheres around this time 
due to bulk erosion. 
 
Figures 2.15 to 2.17 show the radial pH in 11 kDa microspheres. The trends observed at higher 
PLGA molecular weight are not visible with the 11 kDa microspheres. In particular, the data 
suggest that the 11 kDa microspheres undergo an erosive burst around day 14, but the pH drops 
again around day 21. This scenario could occur, given that the PLGA will continue to degrade by 
autocatalytic degradation. However, the extent of the drop would likely be greater in less porous 
microspheres  for all sizes and PLGA molecular weights.  
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Figure 2.7. Confocal micrographs of 45 µm microspheres from 48 kDa PLGA at various 
times during incubation. 
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Figure 2.8. Normalized radial pH of 45 µm from 48 kDa PLGA at various times during 
incubation showing decrease in radial pH over time, with increasing pH at day 21. 
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Figure 2.9. Normalized radial pH of 61 µm from 48 kDa PLGA at various times during 
incubation showing similar radial pH over time, with slight increase in pH at day 21. 
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Figure 2.10. Normalized radial pH of 82 µm from 48 kDa PLGA at various times during 
incubation showing similar radial pH over time, with increase in pH at day 14. 
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Figure 2.11. Normalized radial pH of 46 µm from 25 kDa PLGA at various times during 
incubation showing similar radial pH over time, with slight increase in pH at day 21. 
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Figure 2.12. Normalized radial pH of 67 µm from 25 kDa PLGA at various times during 
incubation showing varied radial pH over time, with increase in pH at day 21. 
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Figure 2.13. Normalized radial pH of 87 µm from 25 kDa PLGA at various times during 
incubation showing varied radial pH over time, with increase in pH at day 21. 
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Figure 2.14. Scanning electron micrographs of 87 µm Microspheres from 48 kDa PLGA 
showing initial surface porosity at day 0. 
 
 
 
 
/ Normalized Radial Position
0.0 0.2 0.4 0.6 0.8 1.0
pH
4
5
6
7
8
Day 1
Day 3
Day 7
Day 14
Day 21
 
Figure 2.15. Normalized radial pH of 43 µm from 11 kDa PLGA at various times during 
incubation showing varied radial pH over time. 
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Figure 2.16. Normalized radial pH of 65 µm from 11 kDa PLGA at various times during 
incubation showing varied radial pH over time. 
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Figure 2.17. Normalized radial pH of 87 µm from 11 kDa PLGA at various times during 
incubation showing similar radial pH over time. 
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2.4.4 Study Validity 
The validity of results observed using the selected dye pair is questionable. The extent of the 
decrease in intensity with decreasing radial position is rather shallow in most microspheres 
regardless of diameter or PLGA molecular weight. Additionally, given the degradation behavior 
of PLGA, it is highly unlikely that the pH would remain basic inside the microsphere, especially 
during the first two weeks of incubation.  
 
Several factors can affect the accuracy of pH measurement in this study. Accurately measuring 
the intensity at the center of the microsphere and relating that intensity to the intensity observed 
at a particular pH inside pH buffered microspheres depends heavily on the ability of the 
fluorescence of the fluorophore to be fully emitted in confocal microscopy. It was mentioned that 
the microspheres exhibit some degree of swelling over time, up to 62%. This swelling increases 
the distance over which the microscope must measure the intensity of fluorescence. Thus, the 
data points may be skewed. It could be that where the radial pH seems to become equal across 
the microsphere diameter, the intensity readings are being affected by the swelling of the 
microspheres.  
 
The intensity values also make determining the pH difficult. If the data were considered to be 
real data, particularly when the pH reaches a value of 4.5, there is no definitive way to determine 
if it would be best to employ FRET analysis at this point, because there is little justification for 
switching to FRET if there are no values across the microsphere that fall below pH 4 when using 
the calibration obtained from natural fluorescence.  
 
Though the pH behavior can be explained in part by diffusion effects, another phenomenon must 
be taken into consideration. Given the clear instances of quenching observed in the standard 
curves, it is difficult to say whether the pH values obtained are real values after the first 
occurrence of pH 4.5. According to the data, most microspheres reach a center pH of around 4.5 
by day 7. It could be that the pH is truly much lower, as shown in previous studies. However, 
low pH does induce a conformational change in albumin that may reduce the instance of energy 
transfer to the acceptor dye at more acidic pH. Thus, the intensities seen may be the full intensity 
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of FAM at low pH. Given that the pH sensitivity of FAM is limited to the range of pH 4 to 7, this 
may also explain why, in some instances, the profiles are flat.    
 
2.5 Conclusions and Future Work 
Overall, this study has shown that pH mapping inside degrading microspheres is of great 
importance. Between previously obtained results and the results of this study, it is clear that the 
pH is heavily influenced by the morphological characteristics of the degrading microsphere, 
including microsphere diameter and initial porosity.   
 
The complexity and sensitivity of fluorescence resonance energy transfer make it a difficult 
technique for application in mapping the radial pH change in degrading PLGA microspheres. 
The combined effect of albumin conformation change and dye pH sensitivity leads to dye 
quenching with changes in pH, making pH mapping difficult to accomplish without questioning 
the validity of the results.  
 
An additional factor is the standard curves themselves. Although a dual dye-conjugated protein 
was found that accomplished FRET for establishing standard curves, two separate curves were 
necessary to fully determine pH: one in the FRET region of interest, one where the natural pH 
sensitivity of the dye was able to provide a standard curve. Only in the higher molecular weight 
PLGA and larger microsphere sizes is quenching minimized to obtain a more consistent standard 
curve over a wider pH range. Also the unpredictable nature of the pH change inside the 
microsphere coupled with the unknown effects of dye quenching made determining the region 
where the FRET curve should be used after the pH first reached a value of 4 an inconclusive 
task.  
 
FRET could still be an option for future work on mapping microsphere pH changes. However, it 
is extremely critical to find a system that would allow observation of pH change without the 
likelihood of quenching interference.  This could potentially be accomplished by using a 
different protein that also undergoes pH-induced conformational change. Alginate may be a 
reasonable option, as it has the capacity for greater incremental conformation changes at varying 
acidic pH [8]. Alginate requires a more complex chemistry than albumin for conjugation with the 
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dyes, and crosslinking must be avoided. It may also be of utility to incorporate LysoSensor 
yellow blue from Molecular Probes, which is attached to high molecular weight dextran, to 
consistently measure pH down to pH 3. Since LysoSensor can only measure to pH 3, it would be 
a useful aid in determining the effectiveness of a modified FRET model. If the size or 
conformation of the encapsulated macromolecule is of interest with respect to pH changes, 
LysoSensor yellow blue could comprise only the pH sensitive portion of the composition.  
 
Upon development of a sound system of measuring the pH, it would be of great interest to 
examine the change in pH not only with respect to PLGA molecular weight and microsphere 
diameter, but with varying degrees of porosity. Porosity can be tailored by varying the PLGA 
concentration and the PVA content in the hardening phase. This would allow coupling of 
porosity parameters with pH change, which is a known critical feature of PLGA degradation, 
erosion, and macromolecule encapsulation behavior. It would also be of interest to develop the 
mapping protocol such that the system of measuring pH can be used consistently between 
encapsulated materials, regardless of protein interactions with PLGA and ionic behaviors inside 
the microsphere. This could be accomplished by a more rigorous treatment of the mapping 
process. 
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Chapter 3. Effect of Macromolecule Size on Release from PLGA Microspheres 
 
3.1 Motivation 
 
PLGA microspheres have been heavily investigated for use in therapeutic delivery. Research has 
shown that, among other factors, the PLGA composition and molecular weight as well as the 
diameter of the microsphere all contribute to the type of therapeutic release [1-6]. The pattern of 
release has also been investigated for several macromolecules and small molecules [1-2, 7-8]. 
Comparative studies have shown a slight effect on the release rate of drug with varying protein 
size at low loading concentrations [9]. However, a deeper understanding of the effect of the 
macromolecule itself on the type of release is still needed. Herein, focus is on the release 
behavior of macromolecules of different size and conformation encapsulated in microspheres of 
PLGA 50:50 lactide:glycolide ratio with molecular weights from 11 kDa to 48 kDa. In particular, 
this study compares the release behavior of bovine serum albumin (66,000 Da) and hen egg-
white lysozyme (14,400 Da). These two macromolecules were chosen for their size and 
conformational differences. Albumin is a globular protein, whereas lysozyme is a smaller, 
elongated compound. This study also examines the potential differences in microsphere surface 
morphology and porosity after formation, and PLGA degradation with respect to each 
macromolecule.  
 
3.2 Methods 
 
3.2.1 Materials 
Poly(D,L-lactide-co-glycolide) (PLGA) polymers of 50:50 lactide:glycolide ratio and inherent 
viscosities (i.v.) of 0.20, 0.41, and 0.61 dL/g, were obtained from Durect Corporation. These 
PLGA polymers are hereafter referred to by their relative molecular weights of 11 kDa, 25 kDa, 
and 48 kDa, respectively. Lyophilized bovine serum albumin was obtained from Sigma-Aldrich, 
and chosen for its large size (66 kDa) and globular form. Lyophilized hen egg-white lysozyme 
was obtained from Sigma-Aldrich, and was chosen for its elongated form and small size (14 
kDa) compared with albumin. Tween 80 was obtained from Fisher Scientific, and used as a 
surfactant during release studies. Phosphate buffered saline tablets were obtained from MP 
Biomedicals, and dissolved in milli-Q water. Poly(vinyl alcohol) (PVA), 88% hydrolyzed, was 
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obtained from Polysciences, dissolved in Milli-Q water, and diluted to the specified 
concentrations. Reagent grade dichloromethane (DCM) and HPLC grade chloroform were 
obtained from Fisher Scientific.  
 
3.2.2 Microsphere Fabrication and Sizing 
 
Uniform microspheres of roughly 40 µm, 60 µm, and 80 µm diameter were fabricated using the 
precision fabrication technique described in chapter 1. In short, PLGA was dissolved in DCM at 
10 % (w/v). Lysozyme or albumin was dissolved in milli-Q water. The amount of water used 
was maintained at a 1:10 (H2O : DCM) ratio. Lysozyme and albumin concentrations were 
selected to provide 10 % (w/w) loading of the PLGA. The PLGA and macromolecule solutions 
were emulsified by sonication on ice at 60% amplitude for 1 minute, and fed into the precision 
fabricator. Carrier phase and emulsion phase flow rates, and frequency and amplitude of 
vibration were selected to produce the desired microsphere size.  
 
Microspheres were collected in 1% PVA solution, and allowed to harden under stirring for three 
hours at room temperature. Microspheres were subsequently washed with three aliquots of milli-
Q water, then frozen and lyophilized for 48 hours prior to use. Lyophilized microspheres were 
stored at -20ºC under desiccant. Microspheres were sized using a Beckman-Coulter Multi-Sizer 
III, with a minimum count of 10,000 microspheres. Microsphere diameters are reported as the 
mean diameter, and include the standard deviation and R90, which is the ratio of the largest to 
smallest microsphere diameters within the 10% outer limits of measurement. 
 
3.2.3 Macromolecule Loading  
 
For each set of microspheres, approximately 5 mg of microspheres were dissolved in 100 µL of 
DMSO. Twenty microliters of the dissolved PLGA and macromolecule solution were pipetted 
into 1 mL of PBS while vortexing. Samples were then incubated at 37ºC for 1 hour with 
agitation, then centrifuged at 10000 rpm for 10 minutes to pellet the polymer. The supernatant 
was removed and replaced with 1 mL of fresh PBS while vortexing. The samples were then 
incubated for an additional 30 minutes at 37ºC. The concentration of protein in the supernatant 
was determined for both supernatants using BCA assay, then summed per set of microspheres. 
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The encapsulation efficiency or loading is reported as the measured concentration of 
macromolecule as a percent of theoretical loading during encapsulation.  
 
3.2.4 In-Vitro Macromolecule Release and PLGA Degradation Studies 
 
Microspheres were subjected to protein release and PLGA degradation using the protocol given 
in chapter 2. Briefly, 10 mg of microspheres were suspended in 1.25 mL of PBS with 0.05% 
Tween 80 (pH 7.2 ± 0.05), and incubated at 37ºC with agitation. One mL of supernatant was 
extracted at various time points, and replaced with fresh buffer. Protein concentration in 
supernatants was determined using BCA assay.  
 
Microsphere surface morphology and porosity changes were observed by scanning electron 
microscopy. Microspheres were washed with milli-Q water three times, then freeze-fractured and 
mounted on carbon tape, and allowed to dry. Prepped samples were sputter coated for 30 seconds 
at 20 mA with gold-palladium using an Emitech K-575 Sputter Coater. Scanning electron 
micrographs were then acquired using a JEOL 6060 LV scanning electron microscope at 5 kV 
accelerating voltage.  
 
PLGA molecular weight changes were monitored using gel permeation chromatography. Briefly, 
samples were washed with milli-Q water three times to remove PBS salt residue, then frozen and 
lyophilized. Lyophilized samples were dissolved in HPLC grade chloroform at 0.1 g/mL, and 
then filtered using a 0.45 µm filter. Samples were then analyzed using a Waters 1515 Isocratic 
HPLC Pump in conjunction with a Waters 717Plus Autosampler and Waters 2414 Refractive 
Index Detector. Three Waters Styragel columns HR 3, HR 4, and HR 4E were used to separate 
the molecular weights. The relative molecular weights were determined against polystyrene 
standards at 0.1g/mL ranging from 580 Da to 299,400 Da. Samples were injected at 40ºC with a 
flow of 1.0 mL/min and HPLC grade chloroform as the mobile phase. Two injections were made 
per sample.  
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3.3 Results and Discussion 
 
3.3.1 Microsphere Fabrication and Initial Characteristics 
 
PLGA molecular weight was determined prior to and after fabrication of macromolecule loaded 
microspheres. The initial molecular weight of the PLGA by intrinsic viscosity based on 
information provided by the manufacturer and from in-lab GPC is shown in Table 3.1. The 
differences in molecular weight can be attributed to the measurement technique itself. GPC 
results are heavily dependent on the GPC unit used, as well as the standards and solvent used. 
Thus all GPC data are relative, and the PLGA molecular weight values presented herein are 
based on the values obtained from in-lab GPC. PLGA molecular weight was not affected by the 
fabrication process.   
 
Table 3.1. PLGA Molecular Weight Prior to Macromolecule Encapsulation 
PLGA Intrinsic 
Viscosity 
Durect® Molecular 
Weight 
In-lab Molecular 
Weight 
0.20 dL/g 10 kDa 11 kDa 
0.41 dL/g 33.9 kDa 25 kDa 
0.61 dL/g 56.7 kDa 48 kDa 
 
 
Lysozyme and albumin microspheres were fabricated according to the previously described 
precision fabrication protocol. The size distributions of microspheres are shown in Figures 3.1 
and 3.2 for lysozyme and albumin, respectively. The size distributions and encapsulation 
efficiency of lysozyme and albumin are shown in Tables 3.2 and 3.3, respectively. No clear trend 
in encapsulation efficiency by particle size or PLGA molecular weight is observable. However, 
the encapsulation efficiency of albumin is 9% higher on average than lysozyme. The lysozyme 
encapsulation efficiency ranges from 51.5% to 92.3%, and is on average 75.5%. The albumin 
encapsulation efficiency is at the lowest 72.3% and at the highest 99.4%, with an average of 
84.2%. Albumin’s higher encapsulation efficiency may also be attributed to its well-known 
capacity to interact with PLGA to form a stabilizing film at the water-oil interface of the 
emulsion [10]. 
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The internal porosity of the microspheres is shown in Figure 3. Generally, the surface appears 
relatively smooth and homogeneous with minor porosity at the surface regardless of PLGA 
molecular weight, microsphere diameter, or encapsulated macromolecule. Studies have shown 
that increasing the solvent extraction rate leads to higher porosity microspheres [15]. Thus, it is 
likely that at the chosen polymer concentration of 10%, the solvent evaporation rate is high 
enough to cause non-homogeneous formation of the microsphere. Thus greater porosity is 
observed at both the surface and inside the microspheres.  
 
Overall, the formation of the microspheres was weakly affected by the size of the encapsulated 
macromolecule. Rather, the dominating effect in microsphere formation and homogeneity 
appears to be the solvent extraction rate. This study has suggested that the behavior of the 
macromolecule during the solidification phase can directly affect the encapsulation efficiency of 
the macromolecule, but not necessarily the formation of the microsphere itself.  
 
Table 3.2. Lysozyme Loading and Microsphere Diameter 
 
PLGA (MW) Microsphere Diameter (µm) / R90 
Encapsulation 
Efficiency (%) 
44 ± 3 / 1.1 51.5 
58 ± 6 / 1.1 86.5 11 kDa 
82 ± 8 / 1.8 67.6 
43 ± 3 / 1.0 88.2 
62 ± 6 / 1.0 62.9 25 kDa 
80 ± 9 / 1.1 80.9 
40 ± 4 / 1.1 92.3 
60 ± 5 / 1.1 69.9 48 kDa 
80 ± 8 / 1.1 79.4 
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Table 3.3. Albumin Loading and Microsphere Diameter 
 
PLGA (MW) Microsphere Diameter (µm) / R90 
Encapsulation 
Efficiency (%) 
45 ± 3 / 1.1 99.4 
65 ± 9 / 1.3 85.1 11 kDa 
83 ± 7 / 2.0 74.6 
39 ± 6 / 1.1 72.3 
63 ± 5 / 1.0 95.8 25 kDa 
80 ± 4 / 1.0 95.0 
38 ± 5 / 1.1 76.7 
57 ± 6 / 1.0 77.7 48 kDa 
79 ± 8 / 1.0 81.0 
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Figure 3.1. Lysozyme Microsphere Size Distributions from a) 11 kDa, b) 25 kDa, and c) 48 kDa PLGA 
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Figure 3.2. Albumin Microsphere Size Distributions from a) 11 kDa, b) 25 kDa, and c) 48 kDa PLGA 
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Figure 3.3. Scanning electron micrographs of lysozyme and albumin microsphere cross-sections at day 0, showing no 
distinctive trend in internal porosity based on encapsulated macromolecule, microsphere diameter, or PLGA molecular 
weight. 
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3.3.2 Lysozyme Release and Microsphere Surface Morphology 
 
Figures 3.4 – 3.6 show the percent of lysozyme released over time with respect to microsphere 
diameter. Figures 3.7 – 3.9 show the percent of lysozyme released over time with respect to 
PLGA molecular weight. Eight to 23 percent lysozyme release was observed during the first 
seven days of incubation, with little initial burst. However, around day 14 or day 21 a noticeable 
increase in the percent of lysozyme released is observed for all microsphere diameters and PLGA 
molecular weights. As shown in Table 3.4, the percent increase in lysozyme release roughly 
doubles between 40 µm and 80 µm for all three molecular weights, and is slightly greater 
between those microspheres made using 48 kDa PLGA. This increase in release rate marks the 
onset of a noticeable trend in the lysozyme release profiles. Particularly, the largest microspheres 
exhibit a greater percentage of release than the 40 µm and 60 µm microspheres from day 14 
onward. This trend becomes increasingly pronounced with increasing PLGA molecular weight. 
This overall trend is expected due to the combined effect of PLGA autocatalytic degradation and 
slowed byproduct diffusion out of larger microspheres. The larger microspheres retain the acidic 
byproducts produced during the degradation process. By day 14, the microspheres have eroded 
enough to reach the threshold pore network and pore sizes across the microsphere to allow 
diffusion of the degradation byproducts and available lysozyme out of the microsphere. Several 
studies have shown a marked 20% decrease in PLGA molecular weight around day 14 and even 
day 21 of incubation under similar conditions [11-12].  The SEM micrograph shown in Figure 
3.10 is representative of the deformation the microspheres undergo at day 14. This deformation 
is an indicator of a loss of mass, i.e. erosion, inside the microspheres. In addition, it should be 
noted that lysozyme, which carries a positive charge, may interact with negatively charged 
PLGA byproduct species. This could aid its transport out of the microspheres in such large 
quantities at this critical point.  
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Table 3.4. Percent Increase in Lysozyme Release at Critical Burst 
Microsphere 
Set 
% Burst  
Time of 
Burst 
44 µm, 11 kDa 17.2 Day 21 
58 µm, 11 kDa 25.0 Day 14 
82 µm, 11 kDa 34.9 Day 21 
43 µm, 25 kDa 16.9 Day 21 
62 µm, 25 kDa 18.9 Day 14 
80 µm, 25 kDa 33.2 Day 14 
40 µm, 48 kDa 18.9 Day 14 
60 µm, 48 kDa 31.6 Day 14 
80 µm, 48 kDa 43.8 Day 14 
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Figure 3.4. Lysozyme release from 40 µm PLGA microspheres showing fastest release from 
48 kDa PLGA microspheres and distinctive burst release. 
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Figure 3.5. Lysozyme release from 60 µm PLGA microspheres showing fastest release from 
48 kDa PLGA microspheres and distinctive burst release. 
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Figure 3.6. Lysozyme release from 80 µm PLGA microspheres showing fastest release from 
48 kDa PLGA microspheres and distinctive burst release. 
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Figure 3.7. Lysozyme release from 11 kDa PLGA microspheres showing fastest release 
from 80 µm microspheres and distinctive burst release. 
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Figure 3.8. Lysozyme release from 25 kDa PLGA microspheres showing fastest release 
from 80 µm microspheres and distinctive burst release. 
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Figure 3.9. Lysozyme release from 48 kDa PLGA microspheres showing fastest release 
from 80 µm microspheres and distinctive burst release. 
 
3.3.3 Albumin Release, and Microsphere Surface Morphology 
 
Figures 3.11 – 3.13 show the percent of albumin released over time with respect to microsphere 
diameter. Figures 3.14 – 3.16 show the percent of albumin released over time with respect to 
PLGA molecular weight. Similar to lysozyme, little initial burst release is observed. However, 
the percentage of albumin released in the first seven days is double that of lysozyme, averaging 
between 16 and 40 percent. Also similar to the lysozyme release, a noticeable increase in the 
percent of albumin released is observed for some microspheres around day 14, and is tabulated in 
Table 3.5. This increase leads to a slightly higher overall percent release in the 80 µm 
microspheres compared with the 40 µm and 60 µm microspheres. However, the trend becomes 
less noticeable with increasing PLGA molecular weight, though the percent burst release shows 
the inverse trend of releasing more with increasing PLGA molecular weight. The increase in 
release that ultimately leads to the higher percent albumin released in the largest microspheres is 
expected, due to the same PLGA erosion and diffusion behavior that affects lysozyme release.  
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Table 3.5. Percent Increase in Albumin Release at Critical Burst 
Microsphere 
Set 
% Burst 
Time of 
Burst 
45 µm, 11 kDa 8.3 Day 21 
65 µm, 11 kDa 9.3 Day 14 
83 µm, 11 kDa 13.4 Day 21 
39 µm, 25 kDa 20.0 Day 21 
63 µm, 25 kDa 15.9 Day 21 
80 µm, 25 kDa 7.1 Day 14 
38 µm, 48 kDa 31.9 Day 21 
57 µm, 48 kDa 17.7 Day 21 
79 µm, 48 kDa 49.1 Day 21 
 
 
 
 
 
Figure 3.10. Scanning electron micrograph of day 14 39 µm, 25 kDa PLGA microspheres 
showing loss of spherical form. 
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Figure 3.11. Albumin release from 40 µm PLGA microspheres showing increase in release 
rate of 48 kDa microspheres after distinctive burst release. 
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Figure 3.12. Albumin release from 60 µm PLGA microspheres showing fastest release from 
48 kDa microspheres and distinctive burst release. 
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Figure 3.13. Albumin release from 80 µm PLGA microspheres showing increase in release 
rate of 48 kDa microspheres after distinctive burst release.. 
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Figure 3.14. Albumin release from 11 kDa PLGA microspheres showing fastest release 
from 80 µm microspheres. 
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Figure 3.15. Albumin release from 25 kDa PLGA microspheres showing fastest release 
from 80 µm microspheres during the first 30 days. 
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Figure 3.16. Albumin release from 48 kDa PLGA microspheres showing similar release 
from 60 µm and 80 µm microspheres. 
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3.3.4 Macromolecule Comparison 
 
Figures 3.17 – 3.22 show lysozyme and albumin release for each microsphere diameter and 
PLGA molecular weight. Surprisingly in most cases, albumin exhibits a higher percent release 
overall compared with lysozyme. However, lysozyme shows a propensity for a higher burst 
release around day 14. In Table 3.6, lysozyme clearly has a higher percent burst release than 
albumin, with the exception of the 40 µm and 80 µm microspheres from 48 kDa PLGA and 40 
µm microspheres from 25 kDa PLGA. Previous studies have shown that lysozyme tends to 
aggregate toward the surface of the microsphere during fabrication more than albumin [13-14]. 
As previously mentioned, lysozyme’s interaction with PLGA may also contribute to its higher 
burst release around day 14. Note that the internal porosity and spherical form of the lysozyme 
and albumin loaded microspheres remain similar over time, as shown in Figure 3.23, alluding to 
the dominance of the macromolecule behavior in obtaining the release profiles observed.  
 
Curiously, there are a series of inverse release trends observable by both microsphere diameter 
and PLGA molecular weight. At the lowest PLGA molecular weight, there is an increase in the 
distinction between the lysozyme and albumin release by microsphere diameter, where at 80 µm 
the albumin clearly releases at a faster rate than lysozyme. However, the inverse of this trend is 
observed with both the 25 kDa and 48 kDa PLGA. With respect to microsphere diameter, the 
behavior of the 40 µm and 60 µm microspheres is similar to that of the 11 kDa PLGA. The 
albumin release is 14% greater for the 25 kDa PLGA and 13% greater for the 48 kDa PLGA than 
lysozyme in the 40 µm microspheres, but nearly the same for both macromolecules in the 11 kDa 
PLGA. An even more definitive trend exists among the 60 µm microspheres, where albumin 
release is 10% greater for the 25 kDa PLGA and 15% greater for the 48 kDa PLGA than 
lysozyme. Oddly, the highest PLGA molecular weight microspheres do not continue this trend. 
Rather, the distinctively larger albumin release is no longer visible beginning with the 60 µm 
microspheres. Closer observation reveals that during the first 7 days of release, albumin releases 
faster than or at the same rate as lysozyme. However, the high burst that lysozyme exhibits 
around day 14 causes the percent release to be similar for both macromolecules. Most 
interestingly, lysozyme release rate decreases significantly compared with the rate of albumin 
release after this burst. As a result, the percentage of albumin released either equals or exceeds 
that of lysozyme at later time points. 
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The differences between lysozyme and albumin release can be explained by several factors, 
namely macromolecule size, aggregation, diffusion, and PLGA erosion. As mentioned 
previously, lysozyme has a propensity to aggregate toward the surface of the microsphere during 
the fabrication process. Thus, a higher percentage of lysozyme is released quickly compared with 
albumin. After the burst around day 14, fundamental diffusion characteristics come into play, 
and lysozyme appears to release more slowly because the remaining portion must diffuse from a 
longer distance than albumin. This is most clearly evidenced with the 40 µm microspheres and 
higher molecular weight PLGA, where erosion is slower, allowing such diffusion characteristics 
to be observed; and at the lower molecular weight PLGA, where the trend becomes increasingly 
pronounced with increased microsphere diameter. However, both the 25 kDa and 48 kDa PLGA 
exhibit this trend to a lesser degree. Instead, the rate of albumin release decreases with 
microsphere diameter. This is a direct result of erosion rate and diffusion characteristics, as well. 
The higher molecular weight PLGA erodes more slowly than the 11 kDa PLGA. In addition, the 
albumin must diffuse longer distances through the larger diameter microspheres. The larger 
diffusion distance, coupled with slower degradation and erosion cause the albumin to remain 
trapped inside the microsphere.  
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Table 3.6 Lysozyme vs. Albumin Percent Increase in Release from Burst 
 
Lysozyme 
Microspheres 
% Burst 
Albumin 
Microspheres
% Burst 
44 µm, 11 kDa 17.2 
45 µm, 11 
kDa 8.3 
58 µm, 11 kDa 25.0 
65 µm, 11 
kDa 9..3 
82 µm, 11 kDa 34.9 
83 µm, 11 
kDa 13.4 
43 µm, 25 kDa 16.9 
39 µm, 25 
kDa 
20.0 
62 µm, 25 kDa 18.9 
63 µm, 25 
kDa 15.9 
80 µm, 25 kDa 33.2 
80 µm, 25 
kDa 7.1 
40 µm, 48 kDa 18.9 
38 µm, 48 
kDa 
31.9 
60 µm, 48 kDa 31.6 
57 µm, 48 
kDa 17.7 
80 µm, 48 kDa 43.8 
79 µm, 48 
kDa 49.1 
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Figure 3.17. Lysozyme vs. albumin release from 11 kDa PLGA microspheres showing 
fastest release from 80 µm albumin-loaded microspheres. 
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Figure 3.18. Lysozyme vs. Albumin Release from 25 kDa PLGA microspheres showing 
fastest release from albumin-loaded microspheres, becoming incrementally less distinctive 
in  60 µm and 80 µm microspheres. 
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Figure 3.19. Lysozyme vs. albumin release from 48 kDa PLGA microspheres showing 
fastest release from albumin-loaded microsphere, with less distinctive release profiles in 80 
µm microspheres. 
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Figure 3.20. Lysozyme vs. albumin Release from 40 µm PLGA microspheres showing more 
distinctive increase in albumin release at larger PLGA molecular weight. 
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Figure 3.21. Lysozyme vs. albumin release from 60 µm PLGA microspheres showing more 
similar release profiles with increasing PLGA molecular weight. 
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Figure 3.22. Lysozyme vs. albumin release from 80 µm PLGA microspheres showing more 
similar release profiles with increasing PLGA molecular weight.
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Figure 3.23. Representative scanning electron micrographs of cross-sectioned microspheres 
through day 14, showing similar internal porosity and spherical structure over time 
between lysozyme and albumin loaded microspheres.
 63
3.4 Conclusions and Future Work 
 
This study has explored the effect of microsphere size and PLGA molecular weight on the 
release properties of two macromolecules of different size, conformation, and PLGA affinity. 
The results of this study suggest that there may be a slight potential for characteristics of a 
macromolecule to influence the encapsulation and release observed from PLGA microspheres of 
various sizes and PLGA molecular weight. However, this study has shown that the microsphere 
size and PLGA molecular weight play more significant roles in determining the release rate of 
the macromolecule. Albumin, a larger more globular protein, exhibited higher encapsulation and 
faster release than lysozyme, a smaller more elongated enzyme. Albumin’s propensity for both 
greater encapsulation and faster release are a result of its better dispersion throughout the 
microsphere and its ionic interaction with PLGA. The propensity of lysozyme to aggregate 
toward the surface of the microsphere during fabrication and its ionic attraction to PLGA leads to 
a larger burst release at the threshold of pore network formation. More notably, larger diameter 
microspheres made using higher molecular weight PLGA can reduce the extent to which the 
larger macromolecule release exceeds that of smaller macromolecule.  It would be of great 
interest to know the extent to which each macromolecule aggregates during the release process, 
and whether the degree and time frame of acidity inside the microspheres affect the formation of 
aggregates with respect to the size and conformation of these molecules. Such information would 
provide greater insight into the behavior and stability of macromolecules inside PLGA 
microspheres.  
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Chapter 4. Effect of Fabrication Technique on Microsphere Surface Morphology and 
Protein Release 
 
4.1 Motivation 
A range of techniques employing various fundamental principles are used to fabricate polymeric 
microparticles for use in drug delivery applications. Spray drying is a common technique used in 
industry [1-2], along with fluid-aided solvent extraction such as with homogenization. However, 
each technique has proven to have advantages and disadvantages. Spray drying offers rapid gas-
aided solvent extraction, but typically has low particle yield. Higher particle yield is 
accomplished through the use of solution-aided solvent extraction. However, studies have shown 
that the encapsulation efficiency of water soluble compounds is typically lower with fluid-aided 
solvent extraction than with gas-aided solvent extraction [1, 3-5]. Equally, studies have shown 
the ability to control the porosity of particles in both solution and gas-aided drying [5,8]. 
However, the capacity of the process to produce narrow size distributions of particles with high 
encapsulation efficiency and high yield varies between techniques. It has been shown that the 
solvent extraction rate plays a significant role in the encapsulation behavior and particle 
formation behavior [6], and that the encapsulated compound of interest may also affect particle 
formation and encapsulation efficiency [6-7]. However, studies have provided little insight into 
the direct effect of the the mechanism of droplet disruption on particle formation and encapsulant 
loading. Herein, two very similar techniques that use solution-aided drying are compared to more 
closely examine the significance of shear-induced droplet disruption on protein encapsulation 
and release rates.  
 
Though the use of spray drying would be a useful step, this study focuses on two fabrication 
techniques of great similarity – one being precision fabrication, the other homogenization. These 
techniques are separated by the direct treatment of the polymer-drug emulsion during particle 
formation, which will allow determination of the effect of shearing on the initial surface 
morphology and protein loading, and subsequent protein release and polymer erosion behavior. 
Future studies involving spray drying and electrospraying will incorporate the added effect of the 
drying process on microsphere formation.  
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In precision fabrication, a laminar polymer-solvent jet is disrupted by periodic acoustic waves to 
form droplets. Thereafter, the droplets are subjected to no further physical breakage, given that 
the proper stir rate during the hardening phase is used to prevent shearing. Additionally, solvent 
extraction at the surface of the particle is aided by the presence of the carrier phase, which 
provides shearing to the polymer-drug stream prior to breaking. With homogenization, however, 
the polymer phase is initially formed as a relatively large droplet when it is introduced to the 
non-solvent bath. Particles are then subjected to additional physical break up by the 
homogenizer. In this case, particles can be broken multiple times.  
 
This study aims to directly observe the effect of each of these techniques on the initial surface 
morphology, including surface smoothness and surface and internal porosity on PLGA 
microspheres, as well as protein encapsulation efficiency. Subsequently, protein release and 
microsphere morphology changes during the degradation process are compared between the 
techniques.  
 
4.2 Methods 
 
4.2.1 Materials 
Poly(D,L-lactide-co-glycolide) (PLGA) polymers of 50:50 lactide:glycolide ratio and inherent 
viscosities (i.v.) of 0.20, 0.41, and 0.61 dL/g, were obtained from Durect Corporation. These 
PLGA polymers are hereafter referred to by their relative molecular weights of 11 kDa, 25 kDa, 
and 48 kDa, respectively. Lyophilized bovine serum albumin was obtained from Sigma-Aldrich. 
Tween 80 was obtained from Fisher Scientific, and used as a surfactant during release studies. 
Phosphate buffered saline tablets were obtained from MP Biomedicals, and dissolved in milli-Q 
water. Poly(vinyl alcohol) (PVA), 88% hydrolyzed, was obtained from Polysciences, dissolved 
in Milli-Q water, and diluted to the specified concentrations. Reagent grade dichloromethane 
(DCM) and HPLC grade chloroform were obtained from Fisher Scientific.  
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4.2.2 Microsphere Fabrication 
Both broadly and narrowly size-distributed microspheres were fabricated for this study using two 
techniques that vary dominantly in the amount of shearing that occurs at the PLGA particle 
surface during fabrication. PPF microspheres of roughly 40 µm diameter were fabricated using 
the precision fabrication technique described in chapter 1. In short, PLGA was dissolved in DCM 
at 10 % (w/v). Lysozyme or albumin was dissolved in milli-Q water. The amount of water used 
was maintained at a 1:10 (H2O : DCM) ratio. Lysozyme and albumin concentrations were 
selected to provide 10 % (w/w) loading of the PLGA. The PLGA and macromolecule solutions 
were emulsified by sonication on ice at 60% amplitude for 1 minute, and fed into the precision 
fabricator. Carrier phase and emulsion phase flow rates, and frequency and amplitude of 
vibration were selected to produce the desired microsphere size. Microspheres were collected in 
1% PVA solution, and allowed to harden under stirring for three hours. Microspheres were 
subsequently washed with three aliquots of milli-Q water, then frozen and lyophilized for 48 
hours prior to use.  
 
Broader distribution microspheres were prepared by homogenization. As with precision 
fabrication, microspheres were prepared by encapsulating bovine serum albumin at 10% loading 
inside PLGA microspheres, using 11 kDa, 25 kDa, and 48 kDa 50:50 PLGA. Dissolved PLGA 
and albumin were emulsified as previously described. The emulsion was then fed into 1% PVA 
using a syringe, while the bath was homogenized at a speed conducive to the production of 
dominantly 40 µm or 20 µm particles, depending on the batch. Microspheres were then hardened 
under stirring for 3 hours prior to sieving. Microspheres were sieved using Endecotts Ltd. 63 µm, 
40 µm, and 20 µm Laboratory Test Seives. 
 
Lyophilized microspheres were stored at -20ºC under desiccant. Microspheres were sized using a 
Beckman-Coulter Multi-Sizer III, with a minimum count of 10,000 microspheres. Microsphere 
diameters are reported as the mean diameter, and include the standard deviation and R90, which 
is the ratio of the largest to smallest microsphere within the 10% outer limits of measurement. 
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4.2.3 Albumin Loading  
For each set of microspheres, approximately 5 mg of microspheres were dissolved in 100 µL of 
DMSO. Twenty microliters of the dissolved PLGA and macromolecule solution were pipetted 
into 1 mL of PBS while vortexing. Samples were then incubated at 37ºC for 1 hour with 
agitation, then centrifuged at 10000 rpm for 10 minutes to pellet the polymer. The supernatant 
was removed and replaced with 1 mL of fresh PBS while vortexing. The samples were then 
incubated for an additional 30 minutes at 37ºC. The concentration of protein in the supernatant 
was determined for both supernatants using BCA assay, then summed per set of microspheres. 
The encapsulation efficiency or loading is reported as the measured concentration of 
macromolecule as a percent of theoretical loading during encapsulation.  
 
4.2.4 In-Vitro Albumin Release and PLGA Degradation Studies 
Microspheres were subjected to protein release and PLGA degradation using the protocol given 
in chapter 2. Briefly, 10 mg of microspheres were suspended in 1.25 mL of PBS with 0.05% 
Tween 80 (pH 7.2 ± 0.05), and incubated at 37ºC with agitation. One mL of supernatant was 
extracted at various time points, and replaced with fresh buffer. Protein concentration in 
supernatants was determined using BCA assay.  
 
Microsphere surface morphology and porosity changes were observed by scanning electron 
microscopy. Microspheres were washed with milli-Q water three times, then freeze-fractured and 
mounted on carbon tape, and allowed to dry. Prepped samples were sputter coated for 30 seconds 
at 20 mA with gold-palladium using a Emitech K-575 Sputter Coater. Scanning electron 
micrographs were then acquired using a JEOL 6060 LV scanning electron microscope at 5 kV 
accelerating voltage.  
 
PLGA molecular weight changes were monitored using gel permeation chromatography. Briefly, 
samples were washed with milli-Q water three times to remove PBS salt residue, then frozen and 
lyophilized. Lyophilized samples were dissolved in HPLC grade chloroform at 0.1 g/mL, and 
then filtered using a 0.45 µm filter. Samples were then analyzed using a Waters 1515 Isocratic 
HPLC Pump in conjunction with a Waters 717Plus Autosampler and Waters 2414 Refractive 
Index Detector. Three Waters Styragel columns HR 3, HR 4, and HR 4E were used to separate 
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the molecular weights. The relative molecular weights were determined against polystyrene 
standards at 0.1g/mL ranging from 580 Da to 299,400 Da. Samples were injected at 40ºC with a 
flow of 1.0 mL/min and HPLC grade chloroform as the mobile phase. Two injections were made 
per sample.  
 
4.3 Results and Discussion 
 
4.3.1 Microsphere Fabrication 
Albumin-encapsulating PLGA microspheres were produced using both precision particle 
fabrication and conventional homogenization/solvent extraction as described above. 
Microspheres fabricated using 11 kDa, 25 kDa, and 48 kDa PLGA and of a wide size-
distribution, were then sieved to 20 µm or 40 µm mean size. Precision fabricated microspheres 
were fabricated in the 40 µm range to compare with homogenizer microspheres. The average 
diameter with standard deviation and albumin loading of both the PPF and homogenizer 
microspheres are shown in Table 4.1. The size distributions of homogenizer microspheres are 
shown in Figure 4.1.  The homogenizer distribution is overlaid with the distribution of PPF 
microspheres of comparable size and same PLGA molecular weight in Figure 4.2. As expected, 
the R90 value for the homogenizer microspheres is 2.0 and above, alluding to the broader size 
distribution. The precision fabricated microspheres are more uniform, with an R90 of 1.1 for 
each. The breadth of the size distributions from each technique are shown in Figure 4.3. Albumin 
loading is between 10% and 38% higher in microspheres of comparable size produced using 
precision fabrication at the highest and lowest PLGA molecular weights, but is 4% lower in 
microspheres using 25 kDa PLGA. The large difference in loading can be attributed to the 
greater instance of breakage each droplet experiences. During homogenization initially large 
droplets are broken into smaller particles, affording previously entrapped protein the opportunity 
to escape.   
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Table 4.1 Average Diameter of Microspheres 
 Homogenizer Microspheres PPF Microspheres 
PLGA 
Molecular 
Weight 
Diameter (µm) 
± St. Dev. / R90 
Albumin 
Loading (%) 
Diameter (µm) 
± St. Dev. / R90 
Albumin 
Loading (%) 
43 ± 14 / 2.1 61.2 45 ± 3 / 1.1 99.4 
11 kDa 
21 ± 7 / 2.5 81.2 --- --- 
41 ± 11 / 2.0 76.6 39 ± 6 / 1.1 72.3 
25 kDa 
29 ± 10 / 2.5 74.3 --- --- 
45 ± 13 / 2.2 65.2 38 ± 5 / 1.1 76.7 
48 kDa 
24 ± 7 / 2.0 65.5 --- --- 
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Figure 4.1. Size distribution of homogenizer microspheres. a) 21 µm, 11 kDa PLGA; b) 43 
µm, 11 kDa PLGA; c) 29 µm, 25 kDa PLGA; d) 41 µm, 25 kDa PLGA; e) 24 µm, 48 kDa 
PLGA; f) 45 µm, 48 kDa PLGA. 
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a b
c  
Figure 4.2. Overlay of PPF and homogenizer microspheres of ~40 µm mean diameter and 
a) 11 kDa, b) 25 kDa, and c) 48 kDa PLGA showing breadth of distribution per technique 
and the volume % at the peak size per batch. 
 
 
    
Figure 4.3 Scanning electron micrographs of PPF (left) and homogenizer (right) 
microspheres showing the breadth of the size distributions from each technique. 
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4.3.2. Microsphere Morphology, PLGA degradation, and In-Vitro Protein Release  
Scanning electron micrographs of homogenizer 20 µm and 40 µm microspheres at various times 
during degradation are shown in Figure 4.4. The initial porosity throughout the microsphere is 
similar between different size batches of microspheres produced by homogenization. However, 
large pores inside some of the microspheres are present in each batch, as shown in Figure 4.5. 
Large pores at the center are visible in some microspheres of 40 µm and larger. This high 
porosity can be attributed first to the solvent evaporation rate, which at 10% PLGA concentration 
in 1% PVA is relatively fast compared with lower PLGA concentrations [10], causing the larger 
pores observed throughout. The hollow centers could in part be a result of droplets being broken 
multiple times and coalescing. Interestingly, the degree of shearing between batches fabricated 
by homogenization shows little effect on the degree of porosity or initial center pore formation. It 
should be noted that the smaller batch sizes were produced at 2500 rpms greater than the rpms 
for the larger batch sizes. 
 
 Figure 4.6 contains micrographs of both PPF and homogenizer microspheres in the 40 µm range 
at various times during degradation. After fabrication, both types of microspheres exhibit similar 
initial internal porosity when comparing only those homogenizer microspheres without large 
center pores. However, no microspheres with large center pores are noticeable in the PPF 
batches. Microspheres produced by both techniques appear to have smooth surfaces with 
submicron pores and some larger pores up to 3 µm. The similarities between the surface of the 
microspheres from both techniques allude to the likelihood that solvent evaporation rate during 
the hardening phase plays a greater role than initial shearing during fabrication in the formation 
of a smooth surface. However, the increased shearing that the homogenizer microspheres are 
subjected to greatly influences not only the batch size distribution, but the internal uniformity 
and loading efficiency of microspheres produced under such conditions.  
 
Despite the large pores at the center, homogenizer and PPF microspheres exhibit similar erosion 
characteristics in surface and internal morphology over time, as evidenced in Figure 4.6.  This is 
expected given the similarity between the surface and internal porosity of the microspheres. As 
shown in Figure 4.7 large center pores in homogenizer microspheres is still visible at day 21, but 
is not necessarily greater in size. Equally, microspheres with large center pores maintain their 
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shape and integrity just as well as more homogeneous microspheres. This is not surprising since 
the wall-thickness of these microspheres with large center pores is at least 45% of the total 
sphere diameter.  
 
Albumin release from homogenizer microspheres of different size but same PLGA molecular 
weight are shown in Figures 4.8 – 4.10. Little burst release is observed; between 3% and 7% 
albumin is released in the first three days. A total of  16% to 17% of the albumin is released in 
the first 28 days from 48 kDa PLGA microspheres, and between 16% and 25% of the albumin is 
released in the first 28 days from 25 kDa PLGA.  
 
A distinctively faster release rate is observed in the 40 µm microspheres than in the 20 µm 
microspheres from 11 kDa PLGA. This particular trend is not necessarily expected at this 
microsphere size range. Rather, it would be expected that due to diffusion time, the 40 µm 
microspheres would release slower than the 20 µm microspheres. However, the observed 
behavior is likely a result of fast PLGA degradation and easier diffusion of larger quantities of 
albumin out of the 40 µm microspheres due to the hollowing effect. This large porosity clearly 
exists even to the surface of some microspheres, and would allow shorter diffusion distances for 
the albumin over a larger surface area. Equally, more of these larger microspheres with large 
center pores are likely present in the 40 µm batches than the 20 µm batches, particularly with the 
lowest molecular weight PLGA, which would allow solvent diffusion to occur faster than the 
higher molecular weight PLGA. However, the percentage of hollowed microspheres per batch 
could not be determined; thus this is purely speculative. 
 
With the 20 µm microspheres albumin release decreases with increasing PLGA molecular 
weight as shown in Figure 4.11. This is expected since higher molecular weight polymer 
degrades and erodes more slowly at smaller microsphere size. At 40 µm, shown in Figure 4.12, 
the lowest molecular weight PLGA is the fastest releasing, but the 25 kDa and 48 kDa PLGA 
have similar rates of albumin release.  
 
Albumin release from PPF and homogenizer microspheres, shown in Figures 4.13 – 4.15, reveals 
a faster release of albumin from homogenizer microspheres made with 11 kDa PLGA, but that 
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albumin releases more slowly from homogenizer microspheres than PPF microspheres when 25 
kDa and 48 kDa PLGA is used. The variability in the release observed can be attributed to 
several factors, dominantly, the breadth of the size distribution of homogenizer microspheres and 
an unknown percentage of those microspheres with large center pores. The data are easily 
skewed by either of these factors, and cannot be conclusively analyzed. However, the data may 
support the theory that a slower evaporation rate comes into play at higher molecular weight 
PLGA. Thus a higher percentage of microspheres with large center pores may actually be present 
in the 11 kDa PLGA microspheres, leading to faster release. But a smaller percentage of 
microspheres with large center pores may be present in the higher molecular weight PLGA 
microspheres, in part supporting slower release rates. This coupled with a much higher 
percentage of same size microspheres in the PPF batches may help explain the release observed. 
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Figure 4.4. Scanning electron micrographs of homogenizer microsphere cross-sections during degradation, showing internal 
porosity. 
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Figure 4.5. Scanning electron micrograph of homogenizer microspheres showing large pore at center,  day 0. 
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Figure 4.6. Scanning electron micrographs of homogenizer and PPF ~40 µm microsphere cross-sections, showing similarities 
in internal porosity during degradation. 
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Figure 4.7. Scanning electron micrographs of homogenizer microspheres showing large pores at center and surface, day 21. 
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Figure 4.8 Albumin release from 20 µm and 40 µm 11 kDa PLGA microspheres 
showing faster release from the 40 µm microspheres. 
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Figure 4.9 Albumin release from 20 µm and 40 µm 25 kDa PLGA microspheres 
showing slightly faster release from 20 µm microspheres. 
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Figure 4.10 Albumin release from 20 µm and 40 µm 48 kDa PLGA microspheres 
showing similar release rates from the two. 
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Figure 4.11 Albumin release from 20 µm PLGA microspheres showing 
incrementally slower release with increasing PLGA molecular weight. 
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Figure 4.12 Albumin release from 40 µm PLGA microspheres showing fastest 
release from 40 µm microspheres. 
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Figure 4.13 Albumin release from 40 µm 11 kDa PLGA homogenizer and PPF 
microspheres, showing faster release from homogenizer microspheres. 
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Figure 4.14 Albumin release from 40 µm 25 kDa PLGA homogenizer and PPF 
microspheres showing faster release from PPF microspheres, and distinctive burst 
release from PPF microspheres. 
Time (Days)
0 5 10 15 20 25 30
%
 A
lb
um
in
 R
el
ea
se
d
0
20
40
60
80
100
45 µm Homogenizer
38 µm PPF
 
Figure 4.15 Albumin release from 40 µm 48 kDa PLGA homogenizer and PPF 
microspheres showing faster release from PPF microspheres, and distinctive burst 
release from PPF microspheres. 
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4.4 Conclusions and Future Work 
 
Shear forces can be damaging to the formation of PLGA microspheres, as demonstrated 
herein. In particular, greater shearing during the fabrication process can lead to the 
development of less homogeneous microparticles with lower protein encapsulation 
efficiencies and faster release rates than desired due to a higher available surface area and 
shorter diffusion distances. The application of greatly reduced shear forces allows 
fundamental diffusion principles to more exclusively govern the homogeneity of 
microspheres and therapeutic encapsulation and retention.  
 
To more definitively characterize the effect of shearing on PLGA microspheres, it would 
be of great benefit to expand this study to include multiple concentrations of PLGA, as 
well as single solution (as opposed to double emulsion) protein encapsulation. The initial 
emulsion or solution factors into the degree of porosity in newly formed PLGA 
microspheres, as well. Quantifying the results of an expanded study in a model that 
relates shear to porosity would also be worthwhile. Furthermore, measuring the porosity 
of the microspheres directly could give greater insight into the percentage of 
microspheres that hollow during formation.  
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